作者
Federico Gatto, Richard A Feelders, Sanne E Franck, Peter M van Koetsveld, Fadime Dogan, Johan M Kros, Sebastian JCMM Neggers, Aart-Jan van der Lely, Steven WJ Lamberts, Diego Ferone, Leo J Hofland
发表日期
2017/6/1
期刊
The Journal of Clinical Endocrinology & Metabolism
卷号
102
期号
6
页码范围
2009-2018
出版商
Endocrine Society
简介
Context
First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly.
Objective
To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)–secreting pituitary adenomas (GH-omas). To correlate responses with the adenoma somatostatin receptor (SSTR) profile.
Design
The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures. SSTR expression was evaluated in adenoma samples.
Setting and Patients
Patients with acromegaly referred to the Erasmus Medical Center (Rotterdam, The Netherlands).
Interventions
OCT and PAS treatment for 72 hours (10 nM).
Main …
学术搜索中的文章
F Gatto, RA Feelders, SE Franck, PM van Koetsveld… - The Journal of Clinical Endocrinology & Metabolism, 2017
